EQS-News: Bio-Gate released half year news report 2024 and best year

PRESS RELEASE

Bio-Gate will be released by the end of the year 2024 and best of luck

• Umsatz concerns a new yield of 3.5 million euros (Previous year: 3.2 million euros)
• Nettoergebnis relates to other ways to develop new projects –1.1 million. Euro (Vorjahr: -0.7 million euros)
• Ausbau des national en international Vertriebs fortgesetzt

Nuremberg/Bremen, September 9, 2024 – Bio-Gate AG (ISIN DE000BGAG981), a new announcement of innovative technologies and individual solutions for healthcare and hygiene, which in the first month of the business year 2024 (as of 31.12.) ranks first 9.4 percent to 3.5 million euros (previous year: 3.2 million euros). Largely in favor of this development, the business field was dermatology and wound care for the human area.

On achievements, EBITDA fell to a higher level for turnover development, new projects and costs for studies at – 1.2 million euros (previous year: -0.6 million euros). The group income for tax and contributions to other companies at the disposal was at -1.1 million euros (previous year: -0.7 million euros).

Balance sheet remains stable

On the active activity of Bilanz, the turnover was at 1.8 million. Euro (31.12.2023: 1.9 million euros) at a new level in the annual figures of 2023. Days reduced the German interest to 2.5 million. Euro (31.12.2023: 3.3 million euros). Background of the war that covers the backbone with a fluid agent, of 0.5 million. Euro (31.12.2023: 1.3 million euros) sank. The passive life reduces the equity of the half-yearly enjoyment to 2.4 million. Euro (31.12.2023: 3.5 million euros). The foreign capital has a term of 2.1 million. Euro (31.12.2023: 1.8 million euros). In the Folge the Own Capital Quote is reduced to 53.4 percent (31.12.2023: 65.6 percent).

Unterschiedliche Entwicklung in de Geschäftsfeldern

The product with cosmetic products offers a trend of products for self-medication, nutrition and well-being. If you make profit with Bio-Gate of the processed products with microsilber and products, the CBD products are inhaled. In the individual trade and in the drugstore are a lot of dermatological product from Bio-Gate with many sales available. While the economy with the European agricultural sectors is dependent on the international economy, this is the case. Total of the allocation in the business field Dermacosmetik and Wundpflege on 1.97 Mio. Euro (Previous year: 1.32 million euros).

In Human-Medizin technology, the long-term cooperation with a good partner from Germany is planned. A solution can be found for the revision implantation of a revision implant and a right for a clinical study. At an international implant repairer, which is putting one of the latest projects for the implant at Revisie-Gelenkersatz into operation, you start a new project in a new project to start and start the Bio-Gate mode. In the framework of individual solutions in Human-Medizin coated Bio-Gate for orthopaedic Revisions Implant. In the first years of 2024, the Erlöse im Geschäftsfeld Medizintechnik – so listen to the veterinary reviews with HyProtect^TM – up to 0.39 million. Euro (Vorjahr: 0.21 million euros).

The range of animal husbandry products sank the Umsatz in the six-month period at 0.83 million euros (previous year: 1.20 million euros). The background of this war is an end-effect from the vanguard, or it is the business field – an all possible information about the management costs – stable. A serious after-sales issue has led the company to hinge on Industry and Hygiene. The first successful projects with the new coating technology IMC have not yet achieved a reduced after-sales issue for hygiene articles for compensation. The night flies die Erlose at 0.09 million euros (previous year: 0.25 million euros). The unit with the services of the tochtergesellschaft QualityLabs BT GmbH flourishes in the first years of 2024 with 0.23 million. Euro (Vorjahr: 0.23 million euros) stable.

Lookout planned for 2024

Bio-Gate AG has been working in the first years in the first years on the development of new projects with a lower EBITDA that yields net profit, nor below the previous development. For the management, the management is one of the most successful German companies with a German EBITDA and a financial management in 2014. The expectation for this forecast is that there are no major concerns with the current development projects and the plans are intended to achieve the marketing of the products.

Remark:

• All Zahlen sind redactieet used in the text.
• The free-based, complete Half-Year Report 2024 can be found on the homepage of Bio-Gate AG www.bio-gate.de.

Contact:

Investor Relations

Bio-Gate AG / Gerd Rückel

Neumeyerstraat 28-34

D-90411 Nuremberg

[email protected]

Phone: +49 (0) 911 477523-444

Mobile +49 (0)152 34221966

Press

Bio-Gate AG

Neumeyerstraat 28-34

D-90411 Nuremberg

[email protected]

Phone: +49 (0) 911 477523-222

About Bio-Gate:

The Health Technology division of Bio-Gate AG is an innovative technology and product developer for healthcare, infection protection and hygiene, which secures healthcare, works raw and unashamed and finds the wool that you can use. These are special materials and substances with antiviral, antimicrobial or biological properties. Bio-Gate AG refines materials and products, which are specialized in medical technology, such as the Beispiel in the coating of implants or wound layers. Darüber would use the bio-Gate technology dermatological cosmetics and wound care products that can contain both consumer and industrial products, antiviral, antimicrobial or biological effects, and come into a zigzag effect.

Disclaimer:

This Veröffentlichung is again an Angebot zum Verkauf nor an Aufforderung zum Kauf von Wertpapers. Die Aktien der Bio-Gate AG (die “Aktien”) remains in the Vereinigten Staaten or “US Persons” (who is defined in Regulation S des US-American Securities Act of 1933 in der jewel gültigen Fassung (der “Securities Act”)) or for the recognition of “US Persons” boats or sales are offered. The paper can be sold.

This publication does not constitute an offer to sell or the solicitation of an offer to buy securities. The shares of Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as that term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The securities have already been sold.